SUNITINIB

Sunitinib received FDA approval on January 26, 2006, for treatment of gastrointestinal stromal tumour (GIST) in patients with disease progression or intolerance to other medications. FDA approval has subsequently extended to sunitinib for additional cancer indications. Before commencing this medication, discuss with your doctor if you have blood disorders, cardiac conditions, liver disease, renal impairment, skin disorders, diabetes, seizure disorders, or thyroid disease. Inform your doctor if you have undergone recent surgery or have planned surgery.

Sunitinib is a targeted therapy medicine used to treat advanced or metastatic kidney cancer, gastrointestinal stromal tumors (GIST), and certain types of pancreatic neuroendocrine tumors (PNET). It also uses in the treatment of medullary thyroid cancer.

Sunitinib is taken orally, in the form of capsules, with a glass of water. The capsules should be swallowed whole and not crushed, chewed, or opened. The recommended dose may vary depending on the type of cancer being treated, the patient's age and weight, and other factors. This medication is usually taken once a day, with or without food, at around the same time each day. If you miss a dose then do not double the dose to compensate for the missed dose.

Sunitinib may cause a range of side effects, which can vary in severity and frequency. Common side effects include fatigue, nausea, vomiting, diarrhea, loss of appetite, hand-foot syndrome, skin discoloration or rash, high blood pressure, headache, hair loss, changes in taste, dry skin, itching, and nosebleeds. More serious side effects can include heart problems, liver problems, kidney problems, lung problems, hemorrhage, hypothyroidism, hypoglycemia, and rare skin reactions. If you experience any side effects while taking this medication, it is important to inform your healthcare provider.

Sunitinib has several warnings that patients should be aware of. It can cause serious and sometimes fatal liver problems, including liver failure and death, which may occur suddenly and without symptoms. It can also cause heart problems, including heart failure and heart attack, which can be fatal in some cases. Patients with pre-existing liver or heart conditions may be at a higher risk of developing these complications. Other warnings include the risk of high blood pressure, bleeding, and gastrointestinal perforation, which can be life-threatening. This medication can also cause thyroid dysfunction, leading to hyperthyroidism or hypothyroidism, and can affect wound healing.

There are several precautions that patients should take when using sunitinib. Patients should inform their healthcare provider of any pre-existing medical conditions, including liver or heart problems, thyroid disorders, bleeding disorders, or gastrointestinal problems. It may also increase the risk of infections, so patients should avoid close contact with people who have infections. Check with your dentist if you have any problems in the mouth, such as mouth pain, swelling, or sores inside the mouth before starting treatment.

If sunitinib has been prescribed to you, it is essential to adhere to your healthcare provider's instructions. During treatment, avoid consuming grapefruit or grapefruit juice, as these can increase blood levels of the medication and may elevate the risk of side effects. Use an effective contraceptive method while taking this medication and for at least four weeks following your final dose. Sunitinib can cause serious adverse effects, making it important that you remain vigilant and well-informed about your treatment. Report any symptoms or changes to your health to your doctor, regardless of how minor they may appear. With appropriate precautions and regular monitoring, sunitinib can be an effective treatment option for certain cancer types.

Pfizer, U.S Drug and food safety administration (FDA), [Revised on Dec 2018], [Accessed on 5th April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021938s035lbl.pdf Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236. Robert J. Thomson; Majid Moshirfar; Yasmyne Ronquillo, Tyrosine Kinase Inhibitors, [Revised on 21st Jan 2021] [Accessed on 5th April 2023], https://www.ncbi.nlm.nih.gov/books/NBK563322/ Pfizer, Electronic Medicines Compendium (EMC) [Revised on Mar 2021] [Accessed on 5th April 2023], https://www.medicines.org.uk/emc/files/pil.7966.pdf KD Tripathi, Anticancer Drugs, Essentials of Medical Pharmacology, 8th Edition, 2019, 915-936